Based on the results of the Phase 3 clinical trial, Molnupiravir is effective against the currently existing SARS-CoV-2 virus variant, and has the potential to stagnate infection of the Omicron SARS-CoV-2 variant with an RT-PCR viral clearance resultJakarta (ANTARA) - PT Kalbe Farma Tbk and PT Amarox Global Pharma announced that they have begun marketing Movfor (Molnupiravir), the newest antiviral drug for COVID-19, in Indonesia.
The drug is intended for therapeutic use for COVID-19 patients aged over 18, who have mild to moderate symptoms, do not require oxygen administration, and have an increased risk of developing a severe infection, based on the latest edition of COVID-19 Management Guidelines in Indonesia.
Molnupiravir has been granted emergency-use authorization from the United States FDA and the Indonesian National Food and Drug Administration for COVID-19 treatment, the companies said.
It was officially launched in Indonesia on February 15, 2022, by PT Amarox Global Pharma.
Related news: Prioritize vaccine booster in places with high social interaction
"Based on the results of the Phase 3 clinical trial, Molnupiravir is effective against the currently existing SARS-CoV-2 virus variant, and has the potential to stagnate infection of the Omicron SARS-CoV-2 variant with an RT-PCR viral clearance result of 100 percent on Day 5," Dr. Sandeep Sur, general manager of PT Amarox Pharma Global, said in a press release issued on Friday.
Mofvor is being sold and used to treat COVID-19 patients in India and in several ASEAN countries, he informed.
Meanwhile, director of PT Kalbe Farma Tbk, Mulia Lie, said that Kalbe had national marketing and distribution infrastructure capabilities and access to health workers, hospitals, and pharmacies.
Related news: Police chief reminds public to comply with health protocols
With its several distribution branches all over the country, the company expects to expedite availability and access of the COVID-19 drug throughout Indonesia, he added.
“Kalbe has collaborated with Amarox as the main partner in the marketing and distribution of COVID-19 antiviral drugs before. The Movfor (Molnupiravir) drug marketing collaboration is a continuation of other COVID-19 drug collaborations, those being Covifor (Remdesivir) and Fluvir (Oseltamivir). These three antiviral drugs will help in expanding the availability of supply of COVID-19 drugs for the public," he said.
Related news: South Kalimantan ordered to accelerate second vaccine distribution
Related news: Sumenep must boost COVID-19 vaccinations: President Jokowi
Translator: Suci Nurhaliza, Mecca Yumna
Editor: Fardah Assegaf
Copyright © ANTARA 2022
